Press release from Companies
Publicerat: 2021-09-20 18:43:01
OSLO, NORWAY - 20 September 2021: On 20 September 2021, an extraordinary general meeting in Genetic Analysis AS (“GA” or “the Company”) took place at 14.00 CET. Today's extraordinary general meeting formally decided on the share capital increase and the issuance of warrants for the IPO. The first day of trading in Genetic Analysis on Spotlight Stock Market is expected to be on 1 October 2021.
Minutes of an extraordinary general meeting An extraordinary general meeting of Genetic Analysis AS (the "Company") was held on 20 September 2021 at 14:00 in the Company's offices in Kabelgata 8, 0580 Oslo. Agenda: 1. Opening of the general meeting by the chairperson of the board The chairperson of the board made a record of the attending Shareholders and the Shareholders represented by proxy. The total number of shares represented was 7,783,487, equal to 45.2% percent of the total number of shares in the Company. No objections were made to the record. The record is enclosed as Appendix 1 to these minutes. 2. Election of a chairperson and a person to co-sign the minutes The decision was unanimous; see the voting result included in Appendix 2 to these minutes. 3. Approval of the notice and the agenda The decision was unanimous; see the voting result included in Appendix 2 to these minutes and on the Company’s webpage. 4. Share capital increase in connection with listing of the Company's shares on Spotlight Stock Market 5. Issuance of warrants series TO 1 6. Issuance of warrants series TO 2 The decision was unanimous; see the voting result included in Appendix 2 to these minutes and on the Company’s webpage. 7. Authorisation to the board of directors to increase the share capital 8. Resignation of the deputy member of the Board Kathryn M. Baker Appendixes available on the Company’s webpage: For further information, please contact: Ronny Hermansen, CEO About Genetic Analysis Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-targeted multiplex approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need of further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA holds 22 highly qualified employees with relevant scientific backgrounds and with competence in bioinformatics, molecular biology, and bioengineering. www.genetic-analysis.com
The chairperson of the board of directors, Kathryn M. Baker, opened the general meeting and gave a report on attendance.
Kathryn M. Baker was elected as chairperson of the meeting.
Tore Grøttum was elected to sign the minutes together with the chair of the meeting.
The notice and the agenda were approved.
The chairperson of the Board presented the proposal in the notice and further that the board proposes that maximum number of shares referred in the notice are issued.
The general meeting passed the following resolution:
The decision was unanimous; see the voting result included in Appendix 2 to these minutes and on the Company’s webpage.
The chairperson of the Board presented the proposal in the notice and further that the board proposes that maximum number of warrants series TO 1 referred in the notice are issued.
The general meeting passed the following resolution:
The decision was unanimous; see the voting result included in Appendix 2 to these minutes and on the Company’s webpage.
The chairperson of the Board presented the proposal in the notice and further that the board proposes that maximum number of warrants series TO 2 referred in the notice are issued.
The general meeting passed the following resolution:
The chairperson of the Board explained that it is desirable that the board is granted authorisation to increase the Company's share capital by up to NOK 5,151,293. The authorisation is equal to the authorisation already resolved by the general meeting on 28 October 2020. It follows from the proposed authorisation that the shareholders’ preferential rights to subscribe to the new shares may be waived.
The proxy shall facilitate for future issuance of shares for contributing additional capital or other assets to the company, to facilitate merger with or acquisitions of other companies and to settle liabilities of the Company, including liabilities derived from the option program for the Board and management.
The general meeting passed the following resolution:
The decision was unanimous; see the voting result included in Appendix 2 to these minutes and on the Company’s webpage.
The chairperson of the Board presented the proposal in the notice.
The general meeting passed the following resolution:
There shall no longer be deputy members to the Board. Accordingly, Giovanni Magni resigns the role as deputy.
The decision was unanimous; see the voting result included in Appendix 2 to these minutes and on the Company’s webpage.
Oslo, 20 September 2021
ChairpersonTore Grøttum
Co-signor
1: List of attending shareholders
2: Overview of votes for each agenda item
3: List of subscribers
E-mail: rh@genetic-analysis.com
